Sehoon Park1, Soojin Lee2, Yaerim Kim3, Yeonhee Lee2, Min Woo Kang2, Kyungdo Han4, Seung Seok Han5, Hajeong Lee5, Jung Pyo Lee6, Kwon Wook Joo5, Chun Soo Lim6, Yon Su Kim5, Dong Ki Kim5. 1. Seoul National University College of Medicine, Seoul, and Armed Forces Capital Hospital, Gyeonggi-do, Korea (S.P.). 2. Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea (S.L., Y.L., M.W.K.). 3. Keimyung University School of Medicine, Daegu, Korea (Y.K.). 4. College of Medicine, Catholic University of Korea, Seoul, Korea (K.H.). 5. Seoul National University Hospital and Kidney Research Institute, Seoul National University College of Medicine, Seoul, Korea (S.S.H., H.L., K.W.J., Y.S.K., D.K.K.). 6. Seoul National University Boramae Medical Center and Kidney Research Institute, Seoul National University College of Medicine, Seoul, Korea (J.P.L., C.S.L.).
Abstract
Background: Population-scale evidence for the association between dynamic changes in metabolic syndrome (MetS) status and alterations in the risk for major adverse cardiovascular events (MACE) is lacking. Objective: To investigate whether recovery from or development of MetS in a population is associated with an altered risk for MACE. Design: Nationwide cohort study. Setting: An analysis based on the National Health Insurance Database of Korea. Participants: A total of 27 161 051 persons who received national health screenings from 2009 to 2014 were screened. Those with a history of MACE were excluded. We determined the MetS status of 9 553 042 persons using the following harmonizing criteria: MetS-chronic (n = 1 486 485), MetS-developed (n = 587 088), MetS-recovery (n = 538 806), and MetS-free (n = 6 940 663). Measurements: The outcome was the occurrence of MACE, including acute myocardial infarction, revascularization, and acute ischemic stroke, identified from the claims database. The incidence rate ratios (IRRs) were calculated with adjustments for body mass index, comorbidity scores, previous metabolic variables, and other clinical or demographic variables. Results: At a median follow-up of 3.54 years, the MetS-recovery group (incidence rate, 4.55 per 1000 person-years) had a significantly lower MACE risk (adjusted IRR, 0.85 [95% CI, 0.83 to 0.87]) than that of the MetS-chronic group (incidence rate, 8.52 per 1000 person-years). The MetS-developed group (incidence rate, 6.05 per 1000 person-years) had a significantly higher MACE risk (adjusted IRR, 1.36 [CI, 1.33 to 1.39]) than that of the MetS-free group (incidence rate, 1.92 per 1000 person-years). Among the MetS components, change in hypertension was associated with the largest difference in MACE risk. Limitation: Limited assessment of mortality and short follow-up. Conclusion: Recovery from MetS was significantly associated with decreased risk for MACE, whereas development of MetS was associated with increased risk. Primary Funding Source: Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.
Background: Population-scale evidence for the association between dynamic changes in metabolic syndrome (MetS) status and alterations in the risk for major adverse cardiovascular events (MACE) is lacking. Objective: To investigate whether recovery from or development of MetS in a population is associated with an altered risk for MACE. Design: Nationwide cohort study. Setting: An analysis based on the National Health Insurance Database of Korea. Participants: A total of 27 161 051 persons who received national health screenings from 2009 to 2014 were screened. Those with a history of MACE were excluded. We determined the MetS status of 9 553 042 persons using the following harmonizing criteria: MetS-chronic (n = 1 486 485), MetS-developed (n = 587 088), MetS-recovery (n = 538 806), and MetS-free (n = 6 940 663). Measurements: The outcome was the occurrence of MACE, including acute myocardial infarction, revascularization, and acute ischemic stroke, identified from the claims database. The incidence rate ratios (IRRs) were calculated with adjustments for body mass index, comorbidity scores, previous metabolic variables, and other clinical or demographic variables. Results: At a median follow-up of 3.54 years, the MetS-recovery group (incidence rate, 4.55 per 1000 person-years) had a significantly lower MACE risk (adjusted IRR, 0.85 [95% CI, 0.83 to 0.87]) than that of the MetS-chronic group (incidence rate, 8.52 per 1000 person-years). The MetS-developed group (incidence rate, 6.05 per 1000 person-years) had a significantly higher MACE risk (adjusted IRR, 1.36 [CI, 1.33 to 1.39]) than that of the MetS-free group (incidence rate, 1.92 per 1000 person-years). Among the MetS components, change in hypertension was associated with the largest difference in MACE risk. Limitation: Limited assessment of mortality and short follow-up. Conclusion: Recovery from MetS was significantly associated with decreased risk for MACE, whereas development of MetS was associated with increased risk. Primary Funding Source: Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.
Authors: J H Siqueira; T S Silva Pereira; A D Moreira; M F H S Diniz; G Velasquez-Melendez; M J M Fonseca; S M Barreto; I M Benseñor; J G Mill; M C B Molina Journal: J Endocrinol Invest Date: 2022-08-13 Impact factor: 5.467
Authors: Sophia Kwon; Myeonggyun Lee; George Crowley; Theresa Schwartz; Rachel Zeig-Owens; David J Prezant; Mengling Liu; Anna Nolan Journal: Am J Respir Crit Care Med Date: 2021-11-01 Impact factor: 21.405
Authors: Jon Magne Letnes; Ida Berglund; Kristin E Johnson; Håvard Dalen; Bjarne M Nes; Stian Lydersen; Hallgeir Viken; Erlend Hassel; Sigurd Steinshamn; Elisabeth Kleivhaug Vesterbekkmo; Asbjørn Støylen; Line S Reitlo; Nina Zisko; Fredrik H Bækkerud; Atefe R Tari; Jan Erik Ingebrigtsen; Silvana B Sandbakk; Trude Carlsen; Sigmund A Anderssen; Maria A Fiatarone Singh; Jeff S Coombes; Jorunn L Helbostad; Øivind Rognmo; Ulrik Wisløff; Dorthe Stensvold Journal: Eur Heart J Date: 2022-06-01 Impact factor: 35.855
Authors: Sehoon Park; Soojin Lee; Yaerim Kim; Yeonhee Lee; Min Woo Kang; Kyungdo Han; Hajeong Lee; Jung Pyo Lee; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Dong Ki Kim Journal: Kidney Res Clin Pract Date: 2020-06-30